Navigation Links
Royalty Pharma Announces that James Reddoch, Ph.D., Joins Management Team
Date:7/8/2008

NEW YORK, July 8 /PRNewswire/ -- Royalty Pharma is pleased to announce that James Reddoch, Ph.D., has joined the company as Executive Vice President, Head of Research. Dr. Reddoch has 17 years of experience in the biotechnology sector. He has spent the last 12 years as an equity analyst, most recently as Managing Director, Biotechnology and Group Head, Healthcare, at FBR Capital Markets. He previously worked at Banc of America Securities, and CIBC World Markets Corp. (now Oppenheimer & Co.). Dr. Reddoch holds a B.A. from Furman University and a Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham. He was a postdoctoral fellow at the Yale University School of Medicine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO )

"The addition of Jim to our management team adds a critical element to our analytical capabilities. He combines a deep scientific knowledge with fundamental research and financial skills," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "As an analyst, Dr. Reddoch has proven to have a unique perspective that has differentiated him from his peers."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with approximately $5 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Abbott's Humira(R), J&J/Centocor's Remicade(R), Pfizer's Lyrica(R), Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).

The company has an eleven year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica(R)
'/>"/>

SOURCE Royalty Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Angiotech to Establish Separate Operating and Royalty Businesses
2. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
3. Royalty Pharma Acquires Royalty Interest in RotaTeq(R) from The Childrens Hospital Foundation for $182 Million
4. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
5. Antibody Engineering Company F-Star Buys Back Royalty Obligations
6. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
7. Cowen Group, Inc. and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team
8. Drug Royalty Corporation Changes Its Name to DRI Capital
9. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
10. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
11. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... The largest international professional organization of scientists ... derivatives thereof has endorsed an educational program that ... challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural Product ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... - New Progression-Free Survival Data Support Picoplatin ... for Metastatic Castration-Resistant Prostate Cancer -- Results ... of Clinical Oncology,s 2009 Genitourinary Cancers Symposium ... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ...
... China, Feb. 25 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... focused on researching,developing, manufacturing and marketing biopharmaceutical products, ... the fourth quarter and,full year ended December 31, ... 11, 2009. , Following ...
... and Sunflower Oils drive better restaurant menu optionsINDIANAPOLIS, Feb. ... significant milestone in North America with the reduction of ... fats over the past three years. Since the market ... by Dow AgroSciences, have replaced more than 340 million ...
Cached Biology Technology:Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 2Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 3Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 4Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer 53SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3
(Date:4/22/2014)... presented Beaumont Health System with prestigious, competitive research ... athletic and nonathletic injuries. , The American ... grant to fund stem cell-based research that could ... ruptured knee anterior cruciate ligament, or ACL. According ... cruciate ligament injury is the over-stretching or tearing ...
(Date:4/22/2014)... a trip to Asia to coordinate with allies ... officials at the Office of Naval Research (ONR) ... (APTEP) as an example of strong and growing ... in the region. , The APTEP program, centered ... supports the development of alternative energy technologies. It ...
(Date:4/22/2014)... how communities can protect themselves from worsening storms. ... New England and the Midwest providing practical and ... goal is to help communities begin the steps ... of Syntectic International, Portland, OR. "It,s important because ... beyond feeling paralyzed from the lack of local ...
Breaking Biology News(10 mins):Beaumont awarded grants to study sports-related injury treatment, improve recovery 2Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... staff scientist at Carnegie,s Department of Embryology, has ... American Academy of Microbiology. Fellows are annually elected ... their records of scientific achievement and original contributions ... single-celled yeast Saccharomyces cerevisiae , Koshland has ...
... bomb plot was uncovered in London in August 2006, ... (S&T) looked to to find ways to not only ... to figure out what those liquids are. Now, S&T-sponsored ... possible solution. They have successfully tested a liquid ...
... CSC (NYSE: CSC ) announced today that ... Operations and Support Services Unrestricted contract by the Department ... indefinite-delivery/indefinite-quantity (IDIQ) contract covers a broad range of services, ... of BTF business and program units. The contract has ...
Cached Biology News:Carnegie's Doug Koshland elected Fellow of the American Academy of Microbiology 2Good liquid, bad liquid 2CSC Awarded Department of Defense Biometrics Contract 2
Recombinant Rat Leptin, CF...
delta-like 1 homolog (Drosophila)...
... 71-18 mutS and ES1301 mutS are mismatch ... of these strains prevents repair of the ... high mutation efficiencies and making them helpful ... Altered Sites II Mutagenesis Systems. Both ES1301 ...
Request Info...
Biology Products: